🇺🇸 FDA
Pipeline program

CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib

LE 8201

Phase 2 small_molecule active

Quick answer

CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib for Common variable immunodeficiency is a Phase 2 program (small_molecule) at Pharming Technologies B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharming Technologies B.V.
Indication
Common variable immunodeficiency
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials